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To determine whether women in KwaZulu-Natal, South 
Africa, with drug-resistant tuberculosis (TB) were more 
likely than men to have extensively drug-resistant TB, 
we reviewed 4,514 adults admitted during 2003–2008 for 
drug-resistant TB. Female sex independently predicted 
extensively drug-resistant TB, even after we controlled for 
HIV infection. This association needs further study.
T
uberculosis (TB) remains a leading infectious cause of 
death worldwide (1), especially where HIV is endemic 
(2). In industrialized countries, outbreaks of drug-resistant 
TB (multidrug-resistant [MDR] and extensively drug-
resistant [XDR] TB) have occurred predominantly among 
male patients (1). However, in South Africa, where TB 
and HIV are endemic, aggregate data suggest that a greater 
proportion of women than men with TB have MDR TB (3).
In South Africa, HIV infection is more prevalent 
among women than men. Nationally, women 25–29 years 
of age have the highest (32.7%) HIV prevalence; for men, 
prevalence peaks at age 30–34 years (25.8%) (4). KwaZulu-
Natal Province, the epicenter of the HIV/AIDS epidemic in 
South Africa, has a high incidence of hospital admissions 
for MDR TB and XDR TB and >70% HIV co-infection 
among MDR TB patients (5). Since 2003, fueled by a 
generalized HIV epidemic, TB incidence in South Africa 
(1) and hospital admissions for MDR TB in KwaZulu-
Natal have doubled (5). Observational studies of MDR TB 
and XDR TB in South Africa report higher proportions 
of female patients with MDR TB or XDR TB (6–9). We 
conducted this study to determine whether women in 
KwaZulu-Natal with drug-resistant TB were more likely 
than men to have XDR TB, even after we controlled for 
HIV and other factors.
The Study
The study design has been described (5). Brieﬂ  y, we 
retrospectively reviewed adult MDR TB and XDR TB 
patients admitted during 2003–2008 for treatment initiation 
to King George V Hospital (KGVH), a public TB-referral 
hospital in KwaZulu-Natal. Admitting physicians and staff 
collected data routinely. During the study period, KGVH 
was the only public hospital in the province authorized 
to initiate treatment for MDR TB and XDR TB, and all 
therapy was initiated on an inpatient basis.
All patients >18 years of age who had culture-conﬁ  rmed 
MDR TB or XDR TB with standard drug susceptibility 
testing were included. Repeat admissions were excluded. 
MDR TB and XDR TB were deﬁ  ned according to standard 
deﬁ  nitions (10). Ethics review committees at the University 
of KwaZulu-Natal and Boston University (Boston, MA, 
USA) approved the study protocol.
We used Fisher exact or χ2 tests to compare categorical 
variables. Medians were compared by using the Wilcoxon-
Mann-Whitney U test. Univariate and multivariate logistic 
regression models were used to estimate odds ratios (ORs) 
and 95% conﬁ  dence intervals (CIs). Statistically signiﬁ  cant 
variables or variables that caused >10% change in the 
univariate OR were included in the multivariate model. 
Interaction terms were assessed by using Wald tests, with 
p<0.2 considered signiﬁ  cant. Test for trend was performed 
by using the Cochran-Armitage test. Analysis was 
performed with SAS version 9.3 software (SAS Institute, 
Inc., Cary, NC, USA).
A total of 4,941 patients with MDR TB or XDR TB 
from throughout KwaZulu-Natal were admitted for 
initiation of drug-resistant TB treatment to KGVH during 
the study period (Figure). Among 4,514 eligible patients 
with MDR TB or XDR TB, women were younger (median 
age [interquartile range] 32 [26–39] vs. 36 [30–44] years), 
more likely to be HIV infected (65% vs. 47%), and more 
likely than men to be receiving antiretroviral therapy (ART) 
(51% vs. 43%) (Table 1). Women with drug-resistant TB 
were more likely than men with drug-resistant TB to have 
XDR TB (p<0.0001).
On univariate analysis, HIV status, ART (among 
HIV-infected), female gender, previous TB treatment, and 
year of admission to KGVH were signiﬁ  cantly associated 
with XDR TB (Table 2). On multivariate analysis, only 
female gender (OR 1.38, 95% CI 1.11–1.73), previous 
TB treatment (OR 2.16, 95% CI 1.09–4.28), and year of 
admission were independently associated with XDR TB. 
In the HIV strata, ART was not signiﬁ  cantly associated 
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with XDR TB after adjustment was made for confounding 
variables. Confounding of ART and XDR TB by year of 
admission among HIV co-infected persons most likely 
resulted from increased XDR TB case ﬁ  nding after a highly 
publicized XDR TB outbreak in 2006 and increased ART 
use after public health rollout of ART in KwaZulu-Natal 
in 2004. The interaction terms HIV × gender, gender × age 
(categorical), and health care worker (HCW) × gender were 
not signiﬁ  cantly associated with XDR TB.
Most (59%) patients admitted with XDR TB were 
women, which did not change signiﬁ  cantly during the study 
period (test for trend p = 0.68). For MDR TB, the data showed 
increasingly more female MDR TB patients admitted over 
the study period (p<0.001) (online Appendix Table, www.
cdc.gov/EID/content/17/10/11-0105-appT.htm).
Conclusions
Our major ﬁ  nding was that women admitted with drug-
resistant TB to KGVH were 38% more likely than men to 
have XDR TB. This association remained signiﬁ  cant after 
adjustment for potential confounding variables, including 
HIV status. Temporal analysis showed persistently more 
women with XDR TB and increasing proportions of women 
with MDR TB during the study period. Together these data 
support the notion that the epidemic of drug-resistant TB 
predominantly affects women in KwaZulu-Natal.
Supporting context comes from observational studies of 
drug-resistant TB in South Africa. In South African studies, 
higher percentages of XDR TB (50%–56%) than MDR TB 
patients (43%–53%) are women (6–9). However, studies 
from low-prevalence HIV settings report fewer women with 
drug-resistant TB. In a study in the United States, few patients 
with MDR TB (36%) or XDR TB (38%) were female (11). 
Similarly, in cohorts from Latvia, Peru, and Russia, lower 
percentages of patients with MDR TB (17%–40%) and 
XDR TB (29%–35%) were female (12–14). Gender 
differences in drug-resistant TB in areas of HIV endemicity 
and low prevalence suggest a possible effect of the AIDS 
epidemic on prevalence of drug-resistant TB in women.
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Figure. Flow diagram for patients with multidrug-resistant (MDR)
and extensively drug-resistant (XDR) tuberculosis (TB) admitted to 
King George V Hospital, KwaZulu-Natal, South Africa, 2003–2008.
Table 1. Characteristics of 4,514 adults >18 years of age with MDR TB and XDR TB admitted to King George V Hospital, KwaZulu-
Natal, South Africa, 2003–2008* 
Characteristic† No. (%) women, n = 2,208 No. (%) men, n = 2,306 p value
HIV status 
  Positive 1,431 (64.8) 1,083 (47.0) <0.0001
  Negative  394 (17.8)  642 (27.8) 
  Unknown  383 (17.3)  581 (25.2) 
HIV positive and ART 
  Yes 731 (51.1) 465 (42.9) <0.0001
  No  700 (48.9)  618 (57.1) 
Health care worker 
  Yes 180 (8.2) 51 (2.2) <0.0001
  No  2,028 (91.8)  2,255 (97.8) 
Previous treatment 
  Yes 1,987 (95.4) 2,127 (94.4) 0.1305
  No  96 (4.6)  127 (5.6) 
Year of hospital admission 
  2003 188 (8.5) 278 (12.1) 0.0011‡
 2004 195 (8.8) 234 (10.1)
 2005 272 (12.3) 283 (12.3)
 2006 358 (16.2) 350 (15.2)
 2007 590 (26.7) 593 (25.7)
 2008 605 (27.4) 568 (24.6)
Type of TB 
  MDR 1,987 (90.0) 2,150 (93.2) <0.0001
  XDR  221 (10.0)  156 (6.8) 
*MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant; ART, antiretroviral therapy. 
†Median patient age (interquartile range): women, 32 y (26–39 y); men, 36 y (30–44 y); p<0.0001.
‡Cochran-Armitage test for trend. Our study has several limitations. We lacked 
details about hospital admission and factors associated 
with referral. Women with XDR TB might have been 
preferentially referred compared with men with XDR 
TB, women with MDR TB, or both. We lacked data on 
HIV factors, such as CD4 T-cell counts, ART adherence, 
and viral load. Similarly, we lacked data on previous TB 
treatment, medications, adherence, and outcome. Finally, 
as a hospital-based retrospective study, factors associated 
with survival to hospital admission, decisions to seek care, 
and referral patterns may introduce bias.
Potential causes of the association between female 
gender and XDR TB are not known. HIV-related factors 
could explain the association of XDR TB and female 
gender. For example, women with drug-resistant TB may 
be more adherent to ART, leading to improved survival, 
and therefore increased time for XDR TB to develop. 
Factors associated with secondary development of 
XDR TB, such as TB medication adherence or previous 
MDR TB treatment, could explain the association between 
XDR TB and female gender (15). Factors associated with 
exposure to drug-resistant TB strains, including location 
and duration of exposure, could explain the association 
of XDR TB and female gender. For example, women 
are more likely to participate in formal and informal 
care work, with potential exposure to drug-resistant TB 
strains, and therefore primary XDR TB might be more 
likely to develop (5).
These results may have major policy implications for 
TB control in KwaZulu-Natal and South Africa. Because 
women are more likely to have XDR TB in KwaZulu-
Natal, efforts should be made to develop gender-sensitive 
interventions to improve diagnosis, treatment, and 
prevention for drug-resistant TB and HIV. Decentralization 
of drug-resistant TB treatment may better accommodate 
women in conjunction with their work, family, and child-
rearing responsibilities. Further studies are needed to 
conﬁ  rm the magnitude and determinants of the association 
between female gender and XDR TB.
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Table 2. Risk factors for XDR TB and MDR TB among adults >18 years of age admitted to King George V Hospital with drug-resistant 
TB, KwaZulu-Natal, South Africa, 2003–2008* 
Risk factor 
No. (%) with XDR TB, 
n = 377 
No. (%) with MDR TB, 
n = 4,137 
OR (95% CI) 
Univariate analysis Multivariate analysis
Sex
 F  221 (58.6)  1,987 (48.0)  1.53 (1.24–1.90)  1.38 (1.11–1.73) 
 M 156 (41.4) 2,150 (52.0) Reference Reference
Age, y† 
 18–35 204 (54.1) 2,265 (54.7) 0.98 (0.79–1.20)  –
 >36 173 (45.9)  1,872 (45.3)  Reference 
HIV status‡ 
 Positive 259 (68.7) 2,255 (54.7) 1.43 (1.10–1.87) 1.19 (0.90–1.56)
 Negative  77 (20.4)  959 (23.2)  Reference  Reference 
 Unknown  41 (10.9)  923 (22.3)  0.55 (0.38–0.82)  0.69 (0.46–1.04) 
Previous TB treatment 
 Yes 359 (97.6) 3,755 (94.6) 2.27 (1.16–4.47) 2.16 (1.09–4.28)
 No  9 (2.5)  215 (5.4)  Reference  Reference 
HIV positive and ART‡ 
 Yes 149 (57.5) 1,047 (46.4) 1.56 (1.21–2.03) –
 No  110 (42.5)  1,208 (53.6)  Reference 
Year of admission 
 2003 6 (1.6) 460 (11.1) Reference Reference
 2004  5 (1.3)  424 (10.2)  0.90 (0.27–2.98)  0.96 (0.27–3.33) 
 2005  36 (9.5)  519 (12.5)  5.32 (2.22–12.74)  5.03 (1.94–12.99) 
 2006  78 (20.7)  630 (15.2)  9.49 (4.10–21.97)  9.26 (3.71–23.13) 
 2007  137 (36.3)  1,046 (25.3)  10.04 (4.40–22.91)  9.14 (3.70–22.60) 
 2008  115 (30.5)  1,058 (25.6)  8.33 (3.64–19.07)  7.45 (3.00–18.50) 
*XDR, extensively drug-resistant; TB, tuberculosis; MDR, multidrug-resistant; OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy. 
†Median age (interquartile range): MDR TB patients 34 y (28–42 y); XDR TB patients, 35 y (29–42 y).     
‡Univariate analysis restricted to HIV-positive persons only. ART use excluded from multivariate analysis because persons receiving ART must be HIV 
infected. XDR TB in Women, South Africa
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